Trials / Completed
CompletedNCT03426865
Role of Axumin PET Scan in Germ Cell Tumor
Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
Detailed description
Investigators aim to perform a prospective study of anti-18F-FACBC PET/CT in patients with NSGCT prior to RPLND, either in the primary setting or in the post-chemotherapy setting. We will correlate histopathologic outcomes from the RPLND specimen and clinical outcomes of recurrence during follow-up to identify the accuracy of anti-18F-FACBC PET/CT in these settings.
Conditions
- Testis Cancer
- Germ Cell Tumor
- Testicular Cancer
- Germ Cell Tumor of Testis
- Germ Cell Tumor, Testicular, Childhood
- Testicular Neoplasms
- Testicular Germ Cell Tumor
- Testicular Yolk Sac Tumor
- Testicular Choriocarcinoma
- Testicular Diseases
- Germ Cell Cancer Metastatic
- Germ Cell Neoplasm of Retroperitoneum
- Germ Cell Cancer, Nos
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axumin PET scan | PET scan prior to RPLND |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2018-02-08
- Last updated
- 2025-08-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03426865. Inclusion in this directory is not an endorsement.